Cargando…

Oral Azacitidine for Maintenance Treatment of Acute Myeloid Leukaemia After Induction Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

The National Institute for Health and Care Excellence (NICE) invited the manufacturer (Celgene) of oral azacitidine (ONUREG), as part of the Single Technology Appraisal (STA) process, to submit evidence for the clinical effectiveness and cost-effectiveness of oral azacitidine for maintenance treatme...

Descripción completa

Detalles Bibliográficos
Autores principales:	Witlox, Willem, Grimm, Sabine, Howick, Jeremy, Armstrong, Nigel, Ahmadu, Charlotte, McDermott, Kevin, Otten, Thomas, Noake, Caro, Wolff, Robert, Joore, Manuela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10322744/ https://www.ncbi.nlm.nih.gov/pubmed/37129774 http://dx.doi.org/10.1007/s40273-023-01272-9

Ejemplares similares

Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Grimm, Sabine E., et al.
Publicado: (2019)

Arsenic Trioxide for Treating Acute Promyelocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Ramaekers, Bram L. T., et al.
Publicado: (2018)

Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Grimm, Sabine E., et al.
Publicado: (2021)

Correction to: Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Grimm, Sabine E., et al.
Publicado: (2022)

Fenfluramine for Treating Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Wijnen, Ben, et al.
Publicado: (2022)

Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Ramaekers, Bram L. T., et al.
Publicado: (2018)

Fluocinolone Acetonide Intravitreal Implant for Treating Recurrent Non-infectious Uveitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Pouwels, Xavier G. L. V., et al.
Publicado: (2019)

Filgotinib for Treating Moderately to Severely Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: van Asselt, Antoinette D. I., et al.
Publicado: (2023)

Filgotinib for Moderate to Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Grimm, Sabine E., et al.
Publicado: (2021)

Durvalumab for the Treatment of Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Witlox, Willem J. A., et al.
Publicado: (2019)

Belimumab for Treating Active Autoantibody-Positive Systemic Lupus Erythematosus: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Otten, Thomas, et al.
Publicado: (2022)

Correction: Belimumab for Treating Active Autoantibody‑Positive Systemic Lupus Erythematosus: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Otten, Thomas, et al.
Publicado: (2023)

Lenalidomide with Rituximab for Previously Treated Follicular Lymphoma and Marginal Zone Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Witlox, Willem J. A., et al.
Publicado: (2020)

Pralsetinib for RET Fusion-Positive Advanced Non-small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Al Khayat, Mohamed N. M. T., et al.
Publicado: (2023)

Trifluridine–Tipiracil for Previously Treated Metastatic Colorectal Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Ramaekers, Bram L. T., et al.
Publicado: (2017)

Ticagrelor for Secondary Prevention of Atherothrombotic Events After Myocardial Infarction: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Pouwels, Xavier G. L. V., et al.
Publicado: (2018)

Abemaciclib in Combination with Endocrine Therapy for Adjuvant Treatment of Hormone Receptor-Positive, HER2-Negative, Node-Positive Early Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Orozco Leal, Giovany, et al.
Publicado: (2023)

EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties
por: Dickson, Rumona, et al.
Publicado: (2018)

Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal
por: Ramaekers, Bram L. T., et al.
Publicado: (2016)

Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Mistry, Hema, et al.
Publicado: (2017)

Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene
por: Blommestein, Hedwig M., et al.
Publicado: (2015)

Correction to: Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Mistry, Hema, et al.
Publicado: (2019)

NICE recommends acalabrutinib for chronic lymphocytic leukaemia
Publicado: (2021)

The impact of rarity in NICE’s health technology appraisals
por: Clarke, Sophie, et al.
Publicado: (2021)

A systematic review of clinical effectiveness and safety for historical and current treatment options for metachromatic leukodystrophy in children, including atidarsagene autotemcel
por: Armstrong, Nigel, et al.
Publicado: (2023)

Decision making in NICE single technological appraisals: How does NICE incorporate patient perspectives?
por: Hashem, Ferhana, et al.
Publicado: (2017)

Rituximab for the First-Line Maintenance Treatment of Follicular Non-Hodgkin’s Lymphoma: A NICE Single Technology Appraisal
por: Greenhalgh, Janette, et al.
Publicado: (2013)

Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal
por: Büyükkaramikli, Nasuh C., et al.
Publicado: (2017)

Biologic agents for rheumatoid arthritis—negotiating the NICE technology appraisals
por: Kiely, Patrick D. W., et al.
Publicado: (2012)

NICE technology appraisals: working with multiple levels of uncertainty and the potential for bias
por: Brown, Patrick, et al.
Publicado: (2011)

FUS-ERG induces late-onset azacitidine resistance in acute myeloid leukaemia cells
por: Asai-Nishishita, Ai, et al.
Publicado: (2023)

Cenegermin for Treating Neurotrophic Keratitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Fleeman, Nigel, et al.
Publicado: (2019)

Audit of data redaction practices in NICE technology appraisals from 1999 to 2019
por: Osipenko, Leeza
Publicado: (2021)

Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine
por: Schlenk, R. F., et al.
Publicado: (2019)

Digital interventions to moderate alcohol consumption in young people: a Cancer Prevention Europe overview of systematic reviews
por: McDermott, Kevin T., et al.
Publicado: (2023)

Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma: An Evidence Review Group Evaluation of the NICE Single Technology Appraisal
por: Thielen, Frederick W., et al.
Publicado: (2018)

Digital interventions to moderate physical inactivity and/or nutrition in young people: a Cancer Prevention Europe overview of systematic reviews
por: McDermott, Kevin T., et al.
Publicado: (2023)

Pegcetacoplan for Treating Paroxysmal Nocturnal Haemoglobinuria: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Bresnahan, Rebecca, et al.
Publicado: (2023)

Comprehensive Review of Methods to Assess Uncertainty in Health Economic Evaluations
por: Otten, Thomas Michael, et al.
Publicado: (2023)

A qualitative study of manufacturers' submissions to the UK NICE single technology appraisal process
por: Kaltenthaler, Eva C, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_7872qein534gujfv7qg3iut84c